Trinity Delta view: MaxCyte remains well positioned and well-funded to continue to support and expand the adoption of its enabling technologies and expertise in cellular based research and development of next-generation gene edited cell therapies. Q122 revenues indicate both robust demand from cell therapy customers and the implied clinical progress at SPL partners. FY22 guidance for the core business is now ahead of MaxCyte’s five-year revenue CAGR (2017-21) of c 23%. We continue to view MaxCyte as a unique and diversified play on the whole cell engineering field, providing broad exposure across cell types, technologies, indications, and approaches. Our valuation is £1.06bn / $1.39bn, equivalent to 1,050p or $13.64 per share.
23 May 2022
Trinity Delta Lighthouse: MaxCyte
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Trinity Delta Lighthouse: MaxCyte
- Published:
23 May 2022 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
Trinity Delta view: MaxCyte remains well positioned and well-funded to continue to support and expand the adoption of its enabling technologies and expertise in cellular based research and development of next-generation gene edited cell therapies. Q122 revenues indicate both robust demand from cell therapy customers and the implied clinical progress at SPL partners. FY22 guidance for the core business is now ahead of MaxCyte’s five-year revenue CAGR (2017-21) of c 23%. We continue to view MaxCyte as a unique and diversified play on the whole cell engineering field, providing broad exposure across cell types, technologies, indications, and approaches. Our valuation is £1.06bn / $1.39bn, equivalent to 1,050p or $13.64 per share.